FDA grants priority review of Genfit-Ipsen liver disease drug - Seeking Alpha
| GNFT Stock | EUR 3.94 0.04 1.01% |
About 61% of Genfit's investor base is looking to short. The analysis of current outlook of investing in Genfit suggests that many traders are alarmed regarding Genfit's prospects. The current market sentiment, together with Genfit's historical and current headlines, can help investors time the market. In addition, many technical investors use Genfit stock news signals to limit their universe of possible portfolio assets.
Genfit |
FDA grants priority review of Genfit-Ipsen liver disease drug Seeking Alpha
Read at news.google.com
 |
Genfit Fundamental Analysis
We analyze Genfit's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Genfit using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Genfit based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Book
Price To Book Comparative Analysis
Genfit is currently under evaluation in price to book category among its peers. Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Genfit Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Genfit stock to make a market-neutral strategy. Peer analysis of Genfit could also be used in its relative valuation, which is a method of valuing Genfit by comparing valuation metrics with similar companies.
Peers
Genfit Related Equities
| DBV | DBV Technologies | 8.33 | ||||
| ALCLS | Cellectis | 1.05 | ||||
| IPH | Innate Pharma | 0.70 | ||||
| NANO | Nanobiotix | 3.73 | ||||
| ADOC | Adocia | 8.70 |
Complementary Tools for Genfit Stock analysis
When running Genfit's price analysis, check to measure Genfit's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genfit is operating at the current time. Most of Genfit's value examination focuses on studying past and present price action to predict the probability of Genfit's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genfit's price. Additionally, you may evaluate how the addition of Genfit to your portfolios can decrease your overall portfolio volatility.
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |